{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:28:16Z","timestamp":1790911696604,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"DOI":"10.1093\/jac\/dki039","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T01:30:49Z","timestamp":1109295049000},"page":"523-527","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection"],"prefix":"10.1093","volume":"55","author":[{"given":"J.","family":"Steward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Lever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. H.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J. G.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,4]]},"reference":[{"key":"key\n\t\t\t\t20171010211233_R1","doi-asserted-by":"crossref","unstructured":"Dance, D. A. B. (1991). Melioidosis: the tip of the iceberg? Clinical Microbiology Reviews4, 52\u201360.","DOI":"10.1128\/CMR.4.1.52"},{"key":"key\n\t\t\t\t20171010211233_R2","doi-asserted-by":"crossref","unstructured":"Koponen, M. A., Zlock, D., Palmer, D. L. et al. (1991). Melioidosis: forgotten, but not gone. Archives of Internal Medicine137, 605\u20138.","DOI":"10.1001\/archinte.1991.00400030135027"},{"key":"key\n\t\t\t\t20171010211233_R3","doi-asserted-by":"crossref","unstructured":"Chaowagul, W., Suputtamongkul, Y., Dance, D. A. B. et al. (1993). Relapse in melioidosis: incidence and risk factors. Journal of Infectious Diseases168, 1181\u20135.","DOI":"10.1093\/infdis\/168.5.1181"},{"key":"key\n\t\t\t\t20171010211233_R4","doi-asserted-by":"crossref","unstructured":"Ip, M., Osterberg, L. G., Chau, P. Y. et al. (1995). Pulmonary melioidosis. Chest108, 1420\u20134.","DOI":"10.1378\/chest.108.5.1420"},{"key":"key\n\t\t\t\t20171010211233_R5","doi-asserted-by":"crossref","unstructured":"Rajchanuvong, A., Chaowagul, W., Suputtamongkol, Y. et al. (1995). A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline and co-trimoxazole for the oral maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene89, 546\u20139.","DOI":"10.1016\/0035-9203(95)90104-3"},{"key":"key\n\t\t\t\t20171010211233_R6","doi-asserted-by":"crossref","unstructured":"Simpson, A. J. H., Suputtamongkol, Y., Smith, M. D. et al. (1999). Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clinical Infectious Diseases29, 381\u20137.","DOI":"10.1086\/520219"},{"key":"key\n\t\t\t\t20171010211233_R7","doi-asserted-by":"crossref","unstructured":"Chetchotisakd, P., Chaowagul, W., Mootsikapun, P. et al. (2001). Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with co-trimoxazole plus doxycycline. American Journal of Tropical Medicine and Hygiene64, 24\u20137.","DOI":"10.4269\/ajtmh.2001.64.24"},{"key":"key\n\t\t\t\t20171010211233_R8","doi-asserted-by":"crossref","unstructured":"Russell, P., Eley, S. M., Ellis, J. et al. (2000). Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. Journal of Antimicrobial Chemotherapy45, 813\u20138.","DOI":"10.1093\/jac\/45.6.813"},{"key":"key\n\t\t\t\t20171010211233_R9","doi-asserted-by":"crossref","unstructured":"White, N. J. (2003). Melioidosis. Lancet361, 1715\u201322.","DOI":"10.1016\/S0140-6736(03)13374-0"},{"key":"key\n\t\t\t\t20171010211233_R10","doi-asserted-by":"crossref","unstructured":"Cheng, A. C., Fisher, D. A., Anstey, N. M. et al. (2004). Outcomes of patients with melioidosis treated with meropenem. Antimicrobial Agents and Chemotherapy48, 1763\u20135.","DOI":"10.1128\/AAC.48.5.1763-1765.2004"},{"key":"key\n\t\t\t\t20171010211233_R11","doi-asserted-by":"crossref","unstructured":"Dance, D. A. B. (2002). Melioidosis. Current Opinion in Infectious Diseases15, 127\u201332.","DOI":"10.1097\/00001432-200204000-00005"},{"key":"key\n\t\t\t\t20171010211233_R12","doi-asserted-by":"crossref","unstructured":"Chaowagul, W. (2000). Recent advances in the treatment of severe melioidosis. Acta Tropica74, 133\u20137.","DOI":"10.1016\/S0001-706X(99)00062-5"},{"key":"key\n\t\t\t\t20171010211233_R13","unstructured":"Health Protection Agency. (2003). Health Protection Agency Interim Guidelines for Action in the Event of a Deliberate Release: Glanders & Melioidosis, version 2.2, 14 August 2003. HPA, London. [Online.] http:\/\/www.hpa.org.uk\/infections\/topics_az\/deliberate_release\/menu.htm (6 April 2004, date last accessed)."},{"key":"key\n\t\t\t\t20171010211233_R14","doi-asserted-by":"crossref","unstructured":"Chaowagul, W., Suputtamongkul, Y., Smith, M. D. et al. (1997). Oral fluoroquinolones for maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene91, 599\u2013601.","DOI":"10.1016\/S0035-9203(97)90044-4"},{"key":"key\n\t\t\t\t20171010211233_R15","doi-asserted-by":"crossref","unstructured":"Ashdown, L. R. & Currie, B. J. (1992). Melioidosis: when in doubt leave the quinolone alone! Medical Journal of Australia157, 427\u20138.","DOI":"10.5694\/j.1326-5377.1992.tb137276.x"},{"key":"key\n\t\t\t\t20171010211233_R16","doi-asserted-by":"crossref","unstructured":"Steward, J., Lever, M. S., Simpson, A. J. H. et al. (2004). Post-exposure prophylaxis and treatment of systemic anthrax in mice with fluoroquinolones. Journal of Antimicrobial Chemotherapy54, 95\u20139.","DOI":"10.1093\/jac\/dkh276"},{"key":"key\n\t\t\t\t20171010211233_R17","unstructured":"National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Third Edition: Approved Standard M7\u2013A3. NCCLS, Villanova, PA, USA."},{"key":"key\n\t\t\t\t20171010211233_R18","doi-asserted-by":"crossref","unstructured":"Dance, D. A. B., Wuthiekanun, V., Chaowagul, W. I. et al. (1989). The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in-vitro and during treatment. Journal of Antimicrobial Chemotherapy24, 295\u2013309.","DOI":"10.1093\/jac\/24.3.295"},{"key":"key\n\t\t\t\t20171010211233_R19","doi-asserted-by":"crossref","unstructured":"Leelarasamee, A. & Bovornkitti, S. (1989). Melioidosis: review and update. Reviews of Infectious Diseases11, 413\u201325.","DOI":"10.1093\/clinids\/11.3.413"},{"key":"key\n\t\t\t\t20171010211233_R20","doi-asserted-by":"crossref","unstructured":"Ashdown, L. R. (1988). In-vitro activities of the newer \u03b2-lactam and quinolone agents against Pseudomonas pseudomallei. Antimicrobial Agents and Chemotherapy32, 1435\u20136.","DOI":"10.1128\/AAC.32.9.1435"},{"key":"key\n\t\t\t\t20171010211233_R21","unstructured":"Centers for Disease Control and Prevention. (2004). Laboratory exposure to Burkholderia pseudomallei\u2014Los Angeles, CA, 2003. Morbidity and Mortality Weekly Report53, 988\u201390."},{"key":"key\n\t\t\t\t20171010211233_R22","doi-asserted-by":"crossref","unstructured":"Currie, B. J., Fisher, D. A., Howard, D. M. et al. (2000). Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clinical Infectious Diseases31, 981\u20136.","DOI":"10.1086\/318116"},{"key":"key\n\t\t\t\t20171010211233_R23","doi-asserted-by":"crossref","unstructured":"Chaowagul, W., Simpson, A. J. H., Suputtamongkol, Y. et al. (1999). A comparison of chloramphenicol, trimethoprim\u2013sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clinical Infectious Diseases29, 375\u201380.","DOI":"10.1086\/520218"},{"key":"key\n\t\t\t\t20171010211233_R24","doi-asserted-by":"crossref","unstructured":"Winton, M. D., Everett, E. D. & Dolan, S. A. (1988). Activities of five new fluoroquinolones against Pseudomonas pseudomallei. Antimicrobial Agents and Chemotherapy32, 928\u20139.","DOI":"10.1128\/AAC.32.6.928"},{"key":"key\n\t\t\t\t20171010211233_R25","doi-asserted-by":"crossref","unstructured":"Chau, P. Y., Ng, W. S., Leung, Y. K. et al. (1986). In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer \u03b2-lactam antibiotics and quinolone derivatives. Journal of Infectious Diseases153, 167\u201370.","DOI":"10.1093\/infdis\/153.1.167"},{"key":"key\n\t\t\t\t20171010211233_R26","doi-asserted-by":"crossref","unstructured":"Ho, P. L., Cheung, T. K. M., Kinoshita, R. et al. (2002). Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy49, 1039\u201346.","DOI":"10.1093\/jac\/dkf035"},{"key":"key\n\t\t\t\t20171010211233_R27","doi-asserted-by":"crossref","unstructured":"Leakey, A. K., Ulett, G. C. & Hirst, R. G. (1998). BALB\/c and C57Bl\/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microbial Pathogenesis24, 269\u201375.","DOI":"10.1006\/mpat.1997.0179"},{"key":"key\n\t\t\t\t20171010211233_R28","doi-asserted-by":"crossref","unstructured":"Ulett, G. C., Norton, R. E. & Hirst, R. G. (1999). Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model. Pathology31, 264\u20137.","DOI":"10.1080\/003130299105106"},{"key":"key\n\t\t\t\t20171010211233_R29","doi-asserted-by":"crossref","unstructured":"Hoppe, I., Brenneke, B., Rohde, M. et al. (1999). Characterization of a murine model of melioidosis: comparison of different strains of mice. Infection and Immunity67, 2891\u2013900.","DOI":"10.1128\/IAI.67.6.2891-2900.1999"},{"key":"key\n\t\t\t\t20171010211233_R30","doi-asserted-by":"crossref","unstructured":"Morris, T. H. (1995). Antibiotic therapeutics in laboratory animals. Laboratory Animals29, 16\u201336.","DOI":"10.1258\/002367795780740393"},{"key":"key\n\t\t\t\t20171010211233_R31","unstructured":"Bristol-Myers Squibb. (2000). Gatifloxacin package insert. Bristol-Myers Squibb, Princeton, NJ, USA."},{"key":"key\n\t\t\t\t20171010211233_R32","doi-asserted-by":"crossref","unstructured":"Miyazaki, E., Miyazaki, M., Chen, J. M. et al. (1999). Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy43, 85\u20139.","DOI":"10.1128\/AAC.43.1.85"},{"key":"key\n\t\t\t\t20171010211233_R33","doi-asserted-by":"crossref","unstructured":"Ji, B., Lounis, N., Maslo, C. et al. (1998). In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy42, 2066\u20139.","DOI":"10.1128\/AAC.42.8.2066"},{"key":"key\n\t\t\t\t20171010211233_R34","doi-asserted-by":"crossref","unstructured":"Lumbiganon, P. & Sookpranee, T. (1992). Ciprofloxacin therapy for localized melioidosis. Pediatric Infectious Disease Journal11, 418\u20139.","DOI":"10.1097\/00006454-199205000-00022"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/4\/523\/2399598\/dki039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T23:01:52Z","timestamp":1586127712000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/4\/523\/801154\/Comparison-of-gatifloxacin-moxifloxacin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki039","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,4]]},"published":{"date-parts":[[2005,4,1]]}}}